Abstract: A method of sterilizing an Intracervical Insemination (ICI) fertility kit, for use in performing self-insemination. Each sterile kit comprises: one to three sets of individually wrapped sterile, disposable, syringes and optionally semen collection jars; printed instructions; and a QR code. The collection jar comprises a snap-on lid, and an inner surface with seamless edges to prevent semen residue. The syringes and optionally the jars are sealed in plastic wraps permeable to air and gas, and impermeable to pathogens; and are sterilized via gamma radiation or ethylene oxide. Fresh or frozen, unwashed or washed, semen is deposited into the jar, pulled into the syringe, and administered cervically during a user's maximum monthly level of luteinizing hormone. The syringe distal end is designed to push all semen out of the syringe then plug the end closed, while preventing semen residue from collecting within the syringe. Large circular syringe handles facilitate stable handling.

Abstract: A sterile Intracervical Insemination (ICI) fertility kit, method of sterilization, and method of use for performing self-insemination. Each sterile kit comprises: up to three sets of individually wrapped sterile, disposable, syringes and semen collection jars; printed instructions; and a QR code. The collection jar comprises a snap-on lid, and an inner surface with seamless edges to prevent semen residue. The syringes and jars are sealed in plastic wraps permeable to air and gas, and impermeable to pathogens; and are sterilized via gamma radiation or ethylene oxide. Fresh or frozen, unwashed or washed, semen is deposited into the jar, pulled into the syringe, and administered cervically during a user's maximum monthly level of luteinizing hormone. The syringe distal end is designed to push all semen out of the syringe then plug the end closed, while preventing semen residue from collecting within the syringe. Large circular syringe handles facilitate stable handling.

Abstract: A sterile Intracervical Insemination (ICI) fertility kit, method of sterilization, and method of use for performing self-insemination. Each sterile kit comprises: up to three sets of individually wrapped sterile, disposable, syringes and semen collection jars; printed instructions; and a QR code. The collection jar comprises a snap-on lid, and an inner surface with seamless edges to prevent semen residue. The syringes and jars are sealed in plastic wraps permeable to air and gas, and impermeable to pathogens; and are sterilized via gamma radiation or ethylene oxide. Fresh or frozen, unwashed or washed, semen is deposited into the jar, pulled into the syringe, and administered cervically during a user's maximum monthly level of luteinizing hormone. The syringe distal end is designed to push all semen out of the syringe then plug the end closed, while preventing semen residue from collecting within the syringe. Large circular syringe handles facilitate stable handling.

Abstract: A fertility kit for performing self-insemination, comprising a package with three sets of sterilized disposable syringes and collection jars. Each fertility syringe comprises: an outer rigid tubular barrel and an inner plunger. The barrel comprises a curved distal end with a small circular distal opening, and a sealed proximal end, and an inner hollow tube housing the plunger. The barrel's proximal end also comprises two opposing circular members to fit a user's fingers; and a plunger flat end fitting in-between. The plunger distal end has a has a funnel-like shape that fits into the barrel curved end to push all the semen out while preventing a backflow. The collection jar comprises a sealable lid, and an inner surface comprising smooth seamless edges. Fresh or frozen, unwashed semen is deposited into the jar, pulled into the syringe, and administered cervically during a user's maximum monthly level of luteinizing hormone.

Abstract: The present invention describes a newly discovered human G-protein coupled receptor and its encoding polynucleotide. Also described are expression vectors, host cells, agonists, antagonists, antisense molecules, and antibodies associated with the polynucleotide and/or polypeptide of the present invention. In addition, methods for treating, diagnosing, preventing, and screening for disorders associated with aberrant cell growth, neurological conditions, and diseases or disorders related to the brain are illustrated.

Abstract: The invention provides a novel human orphan neurotransmitter transporter belonging to the family of Na+/Cl− dependent transporters. Inventive HNTTBMY1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Further provided are methods for utilizing these polypeptides and polynucleotides in therapy and diagnostic assays for such. The transporter of the present invention is expressed highly in the amygdala brain subregion, which is known to be associated with affective disorders. The inventive transporter shares high homology with the rat orphan neurotransmitter transporter termed NTT4.

Abstract: The present invention describes a newly discovered human G-protein coupled receptor and its encoding polynucleotide. Also described are expression vectors, host cells, agonists, antagonists, antisense molecules, and antibodies associated with the polynucleotide and/or polypeptide of the present invention. In addition, methods for treating, diagnosing, preventing, and screening for disorders associated with aberrant cell growth, immunological diseases, neurological conditions, and diseases or disorders related to the spinal cord and brain, as well as breast and colon, are illustrated.

Abstract: The present invention describes a newly discovered human G-protein coupled receptor and its encoding polynucleotide. Also described are expression vectors, host cells, agonists, antagonists, antisense molecules, and antibodies associated with the polynucleotide and/or polypeptide of the present invention. In addition, methods for treating, diagnosing, preventing, and screening for disorders associated with aberrant cell growth, neurological conditions, and diseases or disorders related to the brain are illustrated.